Corrigendum to Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]"
- Liu, X.
- Munro, A. P.
- Feng, S.
- Janani, L.
- Aley, P. K.
- Babbage, G.
- Baxter, D.
- Bula, M.
- Cathie, K.
- Chatterjee, K.
- Dejnirattisai, W.
- Dodd, K.
- Enever, Y.
- Qureshi, E.
- Goodman, A. L.
- Green, C. A.
- Harndahl, L.
- Haughney, J.
- Hicks, A.
- van der Klaauw, A. A.
- Kwok, J.
- Libri, V.
- Llewelyn, M. J.
- McGregor, A. C.
- Minassian, A. M.
- Moore, P.
- Mughal, M.
- Mujadidi, Y. F.
- Holliday, K.
- Osanlou, O.
- Osanlou, R.
- Owens, D. R.
- Pacurar, M.
- Palfreeman, A.
- Pan, D.
- Rampling, T.
- Regan, K.
- Saich, S.
- Serafimova, T.
- Saralaya, D.
- Screaton, G. R.
- Sharma, S.
- Sheridan, R.
- Sturdy, A.
- Supasa, P.
- Thomson, E. C.
- Todd, S.
- Twelves, C.
- Read, R. C.
- Charlton, S.
- Hallis, B.
- Ramsay, M.
- Andrews, N.
- Lambe, T.
- Nguyen-Van-Tam, J. S.
- Cornelius, V.
- Snape, M. D.
- Faust, S. N.
DOIAbstract
unknownThe article is available via Open Access. Click on the 'Additional link' above to access the full-text
Add to ORKG